Access Statistics for Matthew J. Higgins

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Country‑Specific View of Tariffs 1 1 11 15 4 4 27 30
Accounting for Price Endogeneity in Airline Itinerary Choice Models: An Application to Continental U.S. Markets 0 0 0 46 3 4 17 104
Assets with "Warts": How Reliable is the Market for Technology? 0 0 0 8 3 3 7 45
Behind the Scenes: Sources of Complementarity in R&D 0 0 0 16 4 6 19 95
Beyond Price: Rights Trading in Strategic Factor Markets 0 0 0 0 2 2 2 2
Black Populations and Economic Growth: An Extreme Bounds Analysis of Mississippi County-Level Data 1 1 1 38 4 5 17 275
Blockbusters, Sequels and the Nature of Innovation 1 1 2 15 2 2 20 40
Coasian Stakeholder Theory 1 1 1 1 2 2 2 2
Conveying Quality and Value in Emerging Industries: Star Scientists and the Role of Learning in Biotechnology 0 0 0 34 1 2 14 235
Corporate Venture Capital as a Real Option in the Markets for Technology 1 1 2 73 3 5 18 120
Don’t Throw the Baby Out With the Bathwater: Firm Response to Downstream Product Shocks 0 0 0 18 1 1 11 39
Explaining Preferences for Control Rights in Strategic Alliances: A Property Rights and Capabilities Perspective Approach 0 0 0 29 2 2 12 91
Federal, State, and Local Governments: Evaluating their Separate Roles in US Growth 0 0 0 61 1 3 16 442
Federal, State, and Local Governments: Evaluating their Separate Roles in US Growth 0 0 0 47 2 2 8 378
Federal, State, and Local Governments:Evaluating their Separate Roles in US Growth 0 0 0 12 2 4 15 157
Federal, state, and local governments: evaluating their separate roles in US growth 0 0 0 4 3 3 15 55
Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation 0 0 1 42 1 3 20 126
Growth and Convergence across the U.S: Evidence from County-Level Data 0 0 0 255 3 5 33 796
Growth and Convergence across the US: Evidence from County-Level Data 0 0 0 7 1 2 21 119
Growth and Convergence across the US: Evidence from County-Level Data 0 0 0 204 1 1 20 645
Growth and Convergence across the US: Evidence from County-Level Data 0 0 0 15 3 4 16 192
Growth and Convergence across the United States: Evidence from County-Level Data 0 0 0 2 1 3 13 37
Heterogeneity in Convergence Rates and Income Determination across U.S. States: Evidence from County-Level Data 0 0 0 2 1 1 9 107
Heterogeneity in Convergence Rates and Income Determination across U.S. States: Evidence from County-Level Data 0 0 0 209 2 5 14 1,143
Heterogeneous Convergence 0 0 0 39 1 1 16 351
Heterogeneous Convergence 0 0 0 14 2 2 27 120
Heterogeneous Convergence 0 0 0 57 2 3 15 220
Heterogeneous Convergence 0 0 0 15 0 2 21 116
Heterogeneous convergence 0 0 0 2 0 0 11 43
Intra-alliance performance, control rights, and today's split of tomorrow's value 0 0 0 85 1 1 10 236
Many Types of Human Capital and Many Roles in U.S. Growth: Evidence from County-Level Educational Attainment Data 0 0 0 426 4 4 15 3,833
Many Types of Human Capital and Many Roles in U.S. Growth: Evidence from County-Level Educational Attainment Data 0 0 0 11 1 2 7 130
Market Size and Research: Evidence from the Pharmaceutical Industry 0 0 1 18 1 1 11 65
Moving Beyond the Valley of Death: Regulation and Venture Capital Investments in Early-Stage Biopharmaceutical Firms 1 1 3 45 3 3 21 82
Pediatric Drug Adherence and Parental Attention: Evidence from Comprehensive Claims Data 0 0 0 1 1 3 9 22
Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry 0 1 2 59 0 4 21 292
Research and Market Structure: Evidence from an Antibiotic-Resistant Pathogenic Outbreak 0 0 0 2 0 2 16 32
Robust Correlates of County-Level Growth in the U.S 0 0 1 40 3 3 14 191
Robust correlates of county-level growth in the United States 0 0 0 0 1 2 7 21
Sigma Convergence Versus Beta Convergence: Evidence from U.S. County-Level Data 0 0 0 30 3 4 11 142
Sigma Convergence Versus Beta Convergence: Evidence from U.S. County-Level Data (revised version) 0 1 3 39 0 3 13 141
Sigma Convergence versus Beta Convergence: Evidence from U.S. County-Level Data 0 0 0 1 1 1 11 31
Sigma Convergence versus Beta Convergence: Evidence from U.S. County-Level Data 0 0 0 151 3 6 20 551
Sigma-Convergence Versus Beta-Convergence: Evidence from U.S. County-Level Data 0 0 0 522 3 4 16 1,680
Stronger IPR, Better Inclusion? Impact Of WTO Accession On Female AI Inventors in China 0 0 0 14 2 2 12 53
The Direct and Indirect Effects of Small Business Administration Lending on Growth: Evidence from U.S. County-Level Data 0 0 0 56 2 3 15 171
The Direct and Indirect Effects of Small Business Administration Lending on Growth: Evidence from U.S. County-Level Data 0 0 0 46 2 2 15 128
The Effect of Contractual Complexity on Technology Sourcing Agreements 0 0 0 40 2 3 11 271
The Impact of Patenting on New Product Introductions in the Pharmaceutical Industry 0 0 0 120 1 1 11 404
The Long March to Innovation: R&D and Competitive Evolution in the Indian Pharmaceutical Industry 3 3 3 3 11 11 11 11
The Role of Assets In Place: Loss of Market Exclusivity and Investment 0 0 0 11 4 5 19 57
Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling 0 0 0 14 2 2 10 61
Why Investment‑Led Growth Lowers Chinese Living Standards 0 0 2 19 2 4 27 47
Will Peak Demand Roil Global Oil Markets? 0 0 1 4 6 6 16 17
Total Working Papers 9 11 34 3,037 116 164 805 14,794


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Accounting for price endogeneity in airline itinerary choice models: An application to Continental U.S. markets 0 0 4 12 7 8 27 105
Behind the Scenes: Sources of Complementarity in R&D 0 0 0 6 1 2 21 79
Conveying quality and value in emerging industries: Star scientists and the role of signals in biotechnology 0 1 1 25 2 4 26 187
Corporate venture capital as a real option in the markets for technology 0 0 0 6 2 7 34 83
Evaluating the effects of Small Business Administration lending on growth 1 2 5 19 4 6 34 106
Federal, State, and Local Governments: Evaluating Their Separate Roles in US Growth 0 0 0 2 0 0 14 42
Federal, state, and local governments: evaluating their separate roles in US growth 0 0 0 32 2 2 10 197
Generic competition and the incentives for early-stage pharmaceutical innovation 0 0 1 7 2 2 21 43
Growth and Convergence across the United States: Evidence from County-Level Data 0 0 0 4 1 3 15 45
Growth and Convergence across the United States: Evidence from County-Level Data 0 0 2 155 0 1 24 441
Heterogeneous Convergence 0 0 0 3 1 1 20 51
Heterogeneous convergence 0 0 0 40 0 1 14 156
How Reliable Is the Market for Technology? 0 0 0 14 1 2 9 84
Modeling competition among airline itineraries 0 0 2 14 2 4 20 77
Pediatric Drug Adherence and Parental Attention: Evidence From Comprehensive Claims Data 0 0 0 0 2 4 11 11
Productivity and the role of complementary assets in firms' demand for technology innovations 0 0 1 24 3 4 21 132
Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry 0 0 0 11 2 25 37 112
Research and market structure: Evidence from an antibiotic-resistant pathogenic outbreak 0 0 0 0 0 0 15 23
Robust Correlates of County-Level Growth in the U.S 0 0 0 0 1 1 14 65
Robust correlates of county-level growth in the United States 0 0 0 11 4 5 10 61
Sigma Convergence versus Beta Convergence: Evidence from U.S. County-Level Data 0 0 0 293 2 2 10 1,193
Sigma Convergence versus Beta Convergence: Evidence from U.S. County-Level Data 0 0 0 11 2 2 28 70
Sigma Convergence versus Beta Convergence: Evidence from U.S. County‐Level Data 0 1 1 11 2 3 19 64
Strategic Alliances: Trading Ownership for Capabilities 0 0 0 8 0 0 12 55
The allocation of control rights in pharmaceutical alliances 2 2 2 62 4 5 8 173
The balance of payments crisis in the euro area periphery 0 1 2 181 1 3 20 726
The impact of advance purchase deadlines on airline consumers’ search and purchase behaviors 0 0 2 10 3 6 19 78
The outsourcing of R&D through acquisitions in the pharmaceutical industry 0 2 6 379 15 27 53 1,088
Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling 0 0 1 4 2 4 17 37
Total Journal Articles 3 9 30 1,344 68 134 583 5,584


Statistics updated 2026-11-12